Article

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysis

2025-06-11

Abstract excerpt

<h4>Objectives</h4> This work assesses the value created for society and for private sector by Gilead Sciences, Inc. (Gilead) through commercialization of medicines for hepatitis C and HIV from 2012-2020. While Gilead has developed several groundbreaking medicines, the company has also been criticized for its drug pricing, patenting, and profits. This analysis posits the total value created by a medicine derives f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5cfcc102-c5d6-5307-bc5f-30f7fc5d9054
DOI: 10.1101/2025.06.11.25329435

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisDOI 10.1101/2025.06.11.25329435Read

Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claimsSemantic proximity Read

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity Read

Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug DevelopmentSemantic proximity Read

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesSemantic proximity Read

Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in BrazilSemantic proximity Read

Rare Disease Curative Care Expenditure- Financing Scheme-Health Provider- Beneficiary Group Analysis — An Empirical Study in Sichuan Province, ChinaSemantic proximity Read

Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity Read

Innovation for challenges of public health and sustainable growthSemantic proximity Read

Estimated global cost of treating COVID-19, HIV, Hepatitis B and Hepatitis C with approved effective oral medicationsSemantic proximity Read

‘A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug DevelopmentSemantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read